Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1215089 | Journal of Chromatography B | 2008 | 7 Pages |
Abstract
ABT-888, a poly(ADP-ribose) polymerase (PARP) -inhibitor in clinical trials, potentiates DNA-damaging agents. We developed and validated, according to FDA guidelines, an LC–MS assay for sensitive, accurate and precise quantitation of ABT-888 and its metabolite M8 in 0.2 mL human plasma. After ethyl acetate extraction, separation is achieved with a hydro-Synergi column and a 0.1% formic acid in acetonitrile/water-gradient. Detection uses electrospray, positive-mode ionization mass spectrometry. Between 10 (LOQ) and 1000 ng/mL, accuracy was 95.5–98.5% for ABT-888 and 91.4–100.9% for M8, and precision was 0.1–4.9% for ABT-888 and 0–13.7% for M8. The assay is being applied to samples generated in several clinical trials.
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Robert A. Parise, Mohammad Shawaqfeh, Merrill J. Egorin, Jan H. Beumer,